Upcoming Events

Date Event
June 7, 2021
Embargo will be lifted by Asco on abstract title and time of presentation on April 28, 2021.

Oral Presentation Details:

Title: "COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies"

Abstract: 2504

Session: Developmental Therapeutics—Immunotherapy

Date and Time: June 7, 202, 3:00 PM – 6:00 PM EDT

The abstract will be made available by ASCO on May 19, 2021, at 5:00 PM EDT on

The presentation will be made available on Compugen's website at following the conclusion of the presentation.

July 21, 2022

In this interview, Eran Ophir discusses Compugen's exciting approach to immune checkpoint inhibitors for the treatment of cancer and what makes them stand out from the crowd.

September 20, 2022 09:45 AM ET
Compugen participation at Fierce Biotech Summit


  • Yaron Turpaz, Senior Vice President and Senior Advisor, Computational Discovery
Panel: Leverage AI and ML to Advance Discovery and Accelerate Drug Development
September 29, 2022
Compugen participation at Immuno UK


  • Eran Ophir, Senior Vice President, Research and Drug Discovery Compugen

Presentation track: Discovery & Development: Intratumoral Immunotherapies & Antibody Therapies
Presentation title: Potential of PVRIG and TIGIT blockade in addressing immunotherapy resistance
Panel Discussion: Combinatorial Strategies in Immuno-Oncology

December 13, 2022 07:00 AM ET

In this video, Dr. Eran Ophir speaks with VJOncology on the PVRIG research and translational data he presented at SITC 2022.

December 14, 2022 07:00 AM ET

In this video, Dr. Michael Overman, University of Texas MD Anderson Cancer Center, speaks with VJOncology about the data he presented at SITC in microsatellite stable colorectal cancer patients treated with COM701 and nivolumab.

December 19, 2022 07:00 AM ET

In these videos, John W. Moroney, M.D., Associate Professor of Gynecologic Oncology in the Dept. of Obstetrics and Gynecology at the University of Chicago and Oladapo Yeku, M.D., Ph.D., FACP, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program, Massachusetts General Hospital, Boston, MA, speak with OncLive about the data they presented at ESMO-IO in platinum resistant ovarian cancer patients treated with COM701 and nivolumab ± BMS-986207

These videos originally published on, and were republished with permission from the publication